News

Emerging from the HazeTM, a cognitive rehabilitation program, is a combination of didactic and experiential content focused on brain health to provide participants with a toolbox of strategies to help them cope with cancer treatment-related cognitive impairment.

Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.

A proactive, multidisciplinary approach is the best way to address belantamab mafodotin—related keratopathy in patients with multiple myeloma.

A new symptom-management guide designed by oncology nurses helps women with ovarian cancer feel more in control of their symptoms.

A comprehensive literature review underscores research gaps into optimal exercise regimens for childhood cancer survivors.

An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.

In this episode of “The Vitals,” Matt Iwaniec, PsyD, discusses the value of integrated behavioral health programs in cancer care.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

The FDA has initiated a priority review for neoadjuvant nivolumab plus chemotherapy to treat patients with resectable non–small cell lung cancer.

Newly FDA-approved ciltacabtagene autoleucel was found to induce an objective response rate of 98% in patients with relapsed/refractory multiple myeloma.

Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Selinexor, an oral selective inhibitor of nuclear export, demonstrated promising efficacy in increasing progression-free survival among women with advanced endometrial cancer.

Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.

Janice Post-White, PhD, RN, FAAN, an oncology nurse and caregiver, discusses how she handled the guilt she felt following her son’s leukemia diagnosis.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Compared with enzalutamide or abiraterone acetate tablets, olaparib was associated with decreased pain burden and better health-related quality of life in patients with castration-resistant prostate cancer.

Cabozantinib is determined to be a safe treatment option for patients with metastatic renal cell carcinoma whose disease failed to respond to prior immunotherapy combinations.

An expert with Allegheny Health Network discusses the value of behavioral therapy and how access and stigma often play a role in preventing patients from receiving this form of care.

Weekly phone calls from RNs helped reduce the number of severe adverse events experienced by patients receiving ipilimumab for metastatic melanoma.

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Adagrasib is currently being considered for approval as a treatment option for previously treated patients with KRAS G12C-mutated non-small cell lung cancer.

Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Nivolumab plus cabozantinib outperformed sunitinib in maintaining health-related quality of life in patients with advanced renal cell carcinoma.

The FDA set the Under the Prescription Drug User Fee Act date for June 24, 2022.

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

The androgen receptor inhibitor darolutamide prolonged overall survival compared with placebo in patients with at least 6 comorbidities.

Frontline niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

First-line treatment with olaparib plus abiraterone resulted in a 34% risk reduction of radiographic disease progression or death in patients with metastatic castration-resistant prostate cancer.